Indivior Pharmaceuticals Inc. Common Stock (INDV)

FairStock Score: 77/100 — HIGH CONVICTION

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am wary of turnarounds, but Indivior has the markings of one that may be real. In fiscal 2023, the year ended 2023-12-31, it lost $126.0M and diluted EPS was -$0.92. By fiscal 2024, the year ended 2024-12-31, net income was $7.0M and diluted EPS was $0.05. In fiscal 2025, the year ended 2025-12-31, revenue was $1.2B, net income was $210.0M, and diluted EPS was $1.64. The latest filed quarter, fiscal Q2 2026 ended 2026-06-30, showed revenue of $343.0M, net income of $122.0M, and diluted EPS of $0.98. That compares with fiscal Q2 2025 ended 2025-06-30, when revenue was $302.0M, net income was $18.0M, and diluted EPS was $0.14. The recovery is sharp. The business sells buprenorphine-based prescription drugs for opioid dependence, including SUBLOCADE and SUBOXONE Film. That is a focused, specialized niche, but I would not call the moat wide; it depends on a narrow product family. Financial health is mixed. ROCE is 26.4% and the Piotroski F-Score is 7/9, yet trailing free cash flow is -$111.0M and FCF yield is -2.7%, so reported profits are not yet converting into cash. The Altman Z-Score of 1.93 also calls for caution. At the close on 2026-10-13, the price was $35.42 and market cap $4.2B. The P/E is 12.70, EV/EBITDA 10.22, and PEG 0.02. If earnings persist, the price is not demanding. FairStock score is 77/100, and the computed Lynch category is TURNAROUND: returned to profit after a loss within the last three years. I would want more cash generation before calling this a bargain, but the profit trend is real.

In plain English: Indivior makes medicines used to treat opioid dependence, including SUBLOCADE and SUBOXONE Film. The business looks much stronger than a few years ago: it lost money in fiscal 2023 but earned $210.0M in fiscal 2025, and in fiscal Q2 2026 it earned $122.0M. At $35.42 on 2026-10-13, the price looks modest compared with those profits, but the company still burns cash, so it is not a clear bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer